[The effects and new insights of ARB on CKD management].

Takashi Nakamichi, Sadayoshi Itoh

Research output: Contribution to journalReview articlepeer-review


Increasing number of patients suffer from chronic kidney disease (CKD) all over the world. CKD is a risk factor of cardiovascular disease as well as end-stage renal disease. The strategy to reduce CKD patients is pivotal for public health. The most useful treatment is to control blood pressure. Angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) are now recommended as the first choice. The recent clinical studies have provided more and more evidence that ARB is effective for CKD management. A part of mechanisms is beyond blood pressure lowering. Oxidative stress and inflammation may be involved in the mechanisms.

Original languageEnglish
Pages (from-to)783-787
Number of pages5
JournalNippon rinsho. Japanese journal of clinical medicine
Issue number4
Publication statusPublished - 2009 Apr

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of '[The effects and new insights of ARB on CKD management].'. Together they form a unique fingerprint.

Cite this